Chloropyramine is a first-generation antihistamine drug approved in several Eastern European countries such as Russia for the treatment of allergic conjunctivitis, allergic rhinitis, bronchial asthma, and other atopic conditions. Chemically supplied most commonly as the hydrochloride salt for improved water solubility, it acts primarily as an H1 receptor antagonist with significant central nervous system penetration and measurable anticholinergic activity. In practice the active pharmaceutical ingredient (API) is formulated into oral tablets, injectable solutions, topical ointments and ophthalmic preparations; it is characterized by good oral bioavailability, hepatic metabolism to N-dealkylated and N-oxide metabolites, and renal excretion of parent and metabolites. Standard quality control for the substance includes identity testing by IR and mass spectrometry, content assay by validated HPLC, residual solvent analysis by GC, and microbial limits for non-sterile forms. Typical regulatory attention focuses on control of related substances, stability under accelerated conditions, and validated dissolution or release for finished forms.
Parent: Chloropyramine/ Chloropyramine Hydrochloride
Parent: Chloropyramine / Phenoxybenzamine
Parent: Chloropyramine / Phenoxybenzamine
Parent: Chloropyramine
![1-[(4-Chlorophenyl)methyl]-2,3-dihydroimidazo[1,2-a]pyridinium Chloride](https://veeprho.com/wp-content/uploads/2025/01/VE0022660-1-4-Chlorophenyl-methyl-2-3-dihydroimidazo-1-2-a-pyridinium-Chloride.png "1-[(4-Chlorophenyl)methyl]-2,3-dihydroimidazo[1,2-a]pyridinium Chloride")
Parent: Chloropyramine
Commercial batches of chloropyramine hydrochloride are typically controlled to meet an assay specification of approximately 98.0 to 102.0% (as determined by validated HPLC), with total related substances commonly limited to below 1.0% w/w and individual specified impurities typically limited to 0.1 to 0.5% w/w depending on regulatory filing and supplier specification. Known related compounds and degradation products include N-desmethyl chloropyramine, N-oxide derivatives, positional chloro isomers, and minor di-dealkylation products; each of these is normally quantified by HPLC with confirmation by LC-MS when required. Oxidative and hydrolytic degradation pathways are the principal sources of impurities during storage and manufacture, so in-process controls, antioxidant measures and appropriate packaging are employed. Residual solvents, if present from synthesis, are controlled per ICH Q3C and elemental impurities per ICH Q3D; any unspecified impurities above reporting thresholds are investigated and qualified according to ICH guidelines.
Chloropyramine is used to counteract histamine-mediated allergic symptoms and is indicated in some countries for conditions such as allergic conjunctivitis, allergic rhinitis, urticaria and adjunctive treatment in bronchial asthma and other atopic disorders.
Chloropyramine ointment is a topical formulation intended to relieve localized allergic dermatitis, pruritus and inflammation associated with skin allergic reactions; topical use limits systemic exposure but formulation-specific guidance and safety data should be followed.
Chlorpheniramine, a different first-generation H1 antagonist, is used to relieve allergy symptoms such as sneezing, nasal congestion, runny nose and itchy or watery eyes; it has sedative properties and a distinct chemical structure and regulatory status from chloropyramine.
Yes, chloropyramine can cause drowsiness because it is a first-generation antihistamine that crosses the blood brain barrier; concomitant use with other central nervous system depressants increases this risk and patients should be cautioned regarding driving or operating machinery.
